ArticleCureus2026
Utility of Serum Vascular Endothelial Growth Factor and Its Clinico-Histopathological Correlation With Cervical Cancer: A Tertiary Care Centre Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The present study was conducted to evaluate serum vascular endothelial growth factor (VEGF) as a potential biomarker for cervical cancer and to assess its role as a prognostic factor by correlating serum VEGF levels with other clinicohistopathological parameters in patients with cervical cancer. Materials and methods Newly diagnosed patients with cervical cancer confirmed by histopathology in the Department of Pathology over a 12-month period were included in the study. Patients who had not undergone any prior treatment or surgery were enrolled. Serum samples were collected for VEGF estimation, and the analysis was performed using the enzyme-linked immunosorbent assay (ELISA) technique in the Department of Pathology at Mahatma Gandhi Memorial Medical College and Maharaja Yeshwant Rao Holkar Hospital, Indore, India. Results A total of 50 patients were included during the study period. VEGF levels were higher than normal in patients with cervical cancer, with a mean value of 670.89 pg/mL. The VEGF levels increased significantly with tumor grade. However, no significant correlation was observed between VEGF levels and the histopathological type of the tumor. Conclusion The findings support the potential of serum VEGF as a non-invasive prognostic biomarker that may aid in stratifying patients according to disease severity and guiding individualized management strategies. Its significant correlation with tumor burden suggests that it could serve as a valuable tool for monitoring therapeutic response and disease progression. However, further large-scale, prospective, and longitudinal studies are required to validate its clinical utility and establish its role in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.